GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ReNeuron Group PLC (OTCPK:RNUGF) » Definitions » Buyback Yield %

ReNeuron Group (ReNeuron Group) Buyback Yield % : 0.00 (As of Apr. 30, 2024)


View and export this data going back to 2006. Start your Free Trial

What is ReNeuron Group Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

ReNeuron Group's current buyback yield was 0.00%.


ReNeuron Group Buyback Yield % Historical Data

The historical data trend for ReNeuron Group's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ReNeuron Group Buyback Yield % Chart

ReNeuron Group Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.53 -25.12 -0.14 -0.02

ReNeuron Group Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.08 -0.03 - - -

Competitive Comparison of ReNeuron Group's Buyback Yield %

For the Biotechnology subindustry, ReNeuron Group's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ReNeuron Group's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ReNeuron Group's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where ReNeuron Group's Buyback Yield % falls into.



ReNeuron Group Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

ReNeuron Group's Buyback Yield for the fiscal year that ended in Mar. 2023 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0.001) / 4.9741206
=-0.02%

ReNeuron Group's annualized Buyback Yield for the quarter that ended in Sep. 2023 is calculated as

Buyback Yield=Net Issuance of Stock(Annualized) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) * Annualized Factor / Market Cap
=- (0 + 0) * 2 / 5.2599896
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the annualized semi-annual data, the Repurchase of Stock and Issuance of Stock data used here is two times the semi-annual (Sep. 2023) data.


ReNeuron Group Buyback Yield % Related Terms

Thank you for viewing the detailed overview of ReNeuron Group's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


ReNeuron Group (ReNeuron Group) Business Description

Traded in Other Exchanges
Address
Pencoed Business Park, Pencoed, Bridgend, GBR, CF35 5HY
ReNeuron Group PLC is engaged in the field of biotechnology. Its core activities include the research and clinical development of cell-based therapeutics. The company product pipeline includes the human retinal progenitor cell line (hRPC) and CTX neural cell line. It derives revenue from UK and U.S. The company is mainly focusing on the treatment of stroke disability, inherited retinal diseases, and cancer.